LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Covid19: Could other alternatives have been possible?

    Bertolini, Alessandro / Maiolani, Martina / Menatti, Elisabetta / Barbonetti, Claudio / Stiglich, Francesco / Valenti, Donato / Fregoni, Vittorio

    Journal of global antimicrobial resistance

    2020  Volume 22, Page(s) 45–46

    MeSH term(s) COVID-19 ; Humans ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-06-03
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2710046-7
    ISSN 2213-7173 ; 2213-7165
    ISSN (online) 2213-7173
    ISSN 2213-7165
    DOI 10.1016/j.jgar.2020.05.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.

    Ceresoli, Giovanni Luca / Rossi, Giulio / Agustoni, Francesco / Bonomi, Lucia / Borghetti, Paolo / Bulotta, Alessandra / Casartelli, Clelia / Cerea, Giulio / Colonese, Francesca / Del Signore, Ester / Finocchiaro, Giovanna / Gianoncelli, Letizia / Grisanti, Salvatore / Maiolani, Martina / Pagni, Fabio / Proto, Claudia / Rijavec, Erika / Vittimberga, Isabella / Arcangeli, Stefano /
    Filippi, Andrea Riccardo

    Critical reviews in oncology/hematology

    2024  , Page(s) 104247

    Abstract: Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated.: Methods: A group of Italian medical and radiation oncologists with expertise in managing patients ... ...

    Abstract Background: Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated.
    Methods: A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements.
    Results: 32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy.
    Conclusions: While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.
    Language English
    Publishing date 2024-01-31
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2023.104247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Covid19: Could other alternatives have been possible?

    Bertolini, Alessandro / Maiolani, Martina / Menatti, Elisabetta / Barbonetti, Claudio / Stiglich, Francesco / Valenti, Donato / Fregoni, Vittorio

    J Glob Antimicrob Resist

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #505871
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Covid19

    Bertolini, Alessandro / Maiolani, Martina / Menatti, Elisabetta / Barbonetti, Claudio / Stiglich, Francesco / Valenti, Donato / Fregoni, Vittorio

    Journal of Global Antimicrobial Resistance

    Could other alternatives have been possible?

    2020  Volume 22, Page(s) 45–46

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2710046-7
    ISSN 2213-7173 ; 2213-7165
    ISSN (online) 2213-7173
    ISSN 2213-7165
    DOI 10.1016/j.jgar.2020.05.010
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: TRKA expression and

    Mauri, Gianluca / Valtorta, Emanuele / Cerea, Giulio / Amatu, Alessio / Schirru, Michele / Marrapese, Giovanna / Fiorillo, Vincenzo / Recchimuzzo, Patrizia / Cavenago, Ivana Stella / Bonazzina, Erica Francesca / Motta, Valentina / Lauricella, Calogero / Veronese, Silvio / Tosi, Federica / Maiolani, Martina / Rospo, Giuseppe / Truini, Mauro / Bonoldi, Emanuela / Christiansen, Jason /
    Potts, Steven J / Siena, Salvatore / Sartore-Bianchi, Andrea

    Journal of clinical pathology

    2018  Volume 71, Issue 10, Page(s) 926–931

    Abstract: Aims: Neurotrophic Tropomyosin Kinase Receptor 1 (: Methods: Formalin-fixed, paraffin-embedded consecutive samples of different tumour types were tested for TRKA expression. Samples showing TRKA IHC staining in at least 10% of cells were analysed by ... ...

    Abstract Aims: Neurotrophic Tropomyosin Kinase Receptor 1 (
    Methods: Formalin-fixed, paraffin-embedded consecutive samples of different tumour types were tested for TRKA expression. Samples showing TRKA IHC staining in at least 10% of cells were analysed by fluorescence in situ hybridisation to assess
    Results: 1043 samples were tested and annotation for histology was available in 1023. Most of the samples were colorectal adenocarcinoma (CRC) (n=550, 52.7%) and lung adenocarcinoma (n=312, 29.9%). 24 samples (2.3%) were biliary tract carcinoma (BTC). Overall, 17 (1.6%) samples were characterised by TRKA IHC expression (four weak, eight moderate, five strong): 9/17 lung adenocarcinoma, 3/17 CRC, 3/17 BTC, 1/17 thyroid cancer and 1/17 cancer of unknown primary. Of these, 1/17 with strong TRKA IHC staining displayed
    Conclusions: TRKA expression can be found in 1.6% of solid tumours and can be paralleled by
    MeSH term(s) Gene Dosage ; Humans ; Neoplasms/genetics ; Neoplasms/metabolism ; Receptor, trkA/biosynthesis ; Receptor, trkA/genetics
    Chemical Substances NTRK1 protein, human ; Receptor, trkA (EC 2.7.10.1)
    Language English
    Publishing date 2018-05-25
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jclinpath-2018-205124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.139: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.

    Ricotta, Riccardo / Vanzulli, Angelo / Moroni, Mauro / Colnago, Barbara / Oriani, Matteo / Nichelatti, Michele / Sarnataro, Carolina / Venturini, Filippo / Di Bella, Sara / Maiolani, Martina / Giganti, Maria Olga / Sartore-Bianchi, Andrea / Siena, Salvatore

    Clinical colorectal cancer

    2013  Volume 12, Issue 1, Page(s) 45–53

    Abstract: Unlabelled: We show that detection, by week-2 magnetic resonance imaging, of tumor shrinkage >10% in response to therapy with cetuximab or panitumumab for metastatic colorectal carcinoma represents an early indicator of clinical outcome because it is ... ...

    Abstract Unlabelled: We show that detection, by week-2 magnetic resonance imaging, of tumor shrinkage >10% in response to therapy with cetuximab or panitumumab for metastatic colorectal carcinoma represents an early indicator of clinical outcome because it is predictive of the prolongation of progression-free survival and overall survival.
    Purpose: The early identification of patients with metastatic colorectal carcinoma who are likely to benefit from treatment with panitumumab or cetuximab remains of paramount importance. We evaluated whether the early tumor shrinkage assessed by magnetic resonance imaging (MRI) is predictive of long-term outcome to these epidermal growth factor receptor-targeted therapies.
    Patients and methods: Thirty-nine patients with chemorefractory metastatic colorectal carcinoma were treated with cetuximab or panitumumab. The patients were evaluated by unenhanced MRI at baseline, week 2, and week 8 after the beginning of the treatment and by contrast-enhanced computed tomography within 3 months. Early response was defined as a tumor shrinkage ≥ 10% at week-2 MRI, whereas response by contrast-enhanced computed tomography was defined according to standard Response Evaluation Criteria in Solid Tumors 1.1.
    Results: At week-2 MRI, 15 (38.5%) of 39 patients had an early response. Eleven (73.3%) of these 15 early responders then presented a partial response by contrast-enhanced computed tomography, whereas none of the 24 early nonresponders obtained a partial response (P < .0005, Fisher exact test). Median progression-free survival (PFS) was 29.7 and 8 weeks in patients with or without early response, respectively (hazard ratio [HR] 0.156 [95% CI, 0.069-0.355]; P < .0001)]. The median overall survival (OS) was 80 weeks in patients with early response and 23.3 weeks in those without early response, respectively (HR 0.154 [95% CI, 0.057-0.420]; P < .00005]).
    Conclusions: Early detection of tumor response by week-2 MRI without contrast medium is associated with a prediction of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cetuximab ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Image Processing, Computer-Assisted ; Liver Neoplasms/drug therapy ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lymphatic Metastasis ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neoplasm Staging ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Prognosis ; Survival Rate
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; panitumumab (6A901E312A) ; Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2013-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2112638-0
    ISSN 1938-0674 ; 1533-0028
    ISSN (online) 1938-0674
    ISSN 1533-0028
    DOI 10.1016/j.clcc.2012.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5798: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 435: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

    Amatu, Alessio / Somaschini, Alessio / Cerea, Giulio / Bosotti, Roberta / Valtorta, Emanuele / Buonandi, Pasquale / Marrapese, Giovanna / Veronese, Silvio / Luo, David / Hornby, Zachary / Multani, Pratik / Murphy, Danielle / Shoemaker, Robert / Lauricella, Calogero / Giannetta, Laura / Maiolani, Martina / Vanzulli, Angelo / Ardini, Elena / Galvani, Arturo /
    Isacchi, Antonella / Sartore-Bianchi, Andrea / Siena, Salvatore

    British journal of cancer

    2015  Volume 113, Issue 12, Page(s) 1730–1734

    Abstract: Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.: Methods: We detected ALK protein ... ...

    Abstract Background: Activated anaplastic lymphoma kinase (ALK) gene fusions are recurrent events in a small fraction of colorectal cancers (CRCs), although these events have not yet been exploited as in other malignancies.
    Methods: We detected ALK protein expression by immunohistochemistry and gene rearrangements by fluorescence in situ hybridisation in the ALKA-372-001 phase I study of the pan-Trk, ROS1, and ALK inhibitor entrectinib. One out of 487 CRCs showed ALK positivity with a peculiar pattern that prompted further characterisation by targeted sequencing using anchored multiplex PCR.
    Results: A novel ALK fusion with the carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) gene (CAD-ALK fusion gene) was identified. It resulted from inversion within chromosome 2 and the fusion of exons 1-35 of CAD with exons 20-29 of ALK. After failure of previous standard therapies, treatment of this patient with the ALK inhibitor entrectinib resulted in a durable objective tumour response.
    Conclusions: We describe the novel CAD-ALK rearrangement as an oncogene and provide the first evidence of its drugability as a new molecular target in CRC.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Aspartate Carbamoyltransferase/genetics ; Benzamides/therapeutic use ; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)/genetics ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Dihydroorotase/genetics ; Female ; Gene Rearrangement ; Humans ; Indazoles/therapeutic use ; Middle Aged ; Receptor Protein-Tyrosine Kinases/genetics
    Chemical Substances Antineoplastic Agents ; Benzamides ; CAD trifunctional enzyme ; Indazoles ; Aspartate Carbamoyltransferase (EC 2.1.3.2) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; anaplastic lymphoma kinase (EC 2.7.10.1) ; Dihydroorotase (EC 3.5.2.3) ; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) (EC 6.3.5.5) ; entrectinib (L5ORF0AN1I)
    Language English
    Publishing date 2015-12-22
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/bjc.2015.401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top